Related Experiment Videos
Cyclooxygenase-2 expression in human pituitary tumors
Sergio Vidal1, Kalman Kovacs, David Bell
1Department of Laboratory Medicine and Pathobiology, St. Michaels Hospital, University of Toronto, Ontario, Canada.
Cancer
|May 27, 2003
Summary
Cyclooxygenase-2 (COX-2) is highly expressed in most pituitary tumors and correlates with angiogenesis. Targeting COX-2 may offer a new therapeutic strategy for pituitary tumors by suppressing blood vessel growth.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Cyclooxygenase-2 (COX-2) is implicated in the progression of various carcinomas.
- The role of COX-2 in pituitary tumors remains to be fully elucidated.
Purpose of the Study:
- To investigate the expression of COX-2 in human pituitary tumors.
- To determine the correlation of COX-2 expression with tumor characteristics and angiogenesis.
Main Methods:
- Evaluated COX-2 expression in 164 surgically removed pituitary tumors using immunohistochemistry.
- Assessed correlations with MIB-1, patient demographics, tumor type, size, invasiveness, and angiogenesis markers.
Main Results:
- 96% of pituitary tumors showed COX-2 immunoreactivity, with higher intensity and percentage of positive cells compared to normal tissue.
- COX-2 expression was significantly correlated with patient age and angiogenesis markers (microvessel density, surface density).
- High COX-2 levels were observed in male gonadotroph and null cell adenomas, while other adenoma types showed lower expression. Macroadenomas had higher expression than microadenomas.
Conclusions:
- COX-2 expression is prevalent in pituitary tumors and is linked to angiogenesis.
- Pharmacological inhibition of COX-2 may represent a novel therapeutic approach to suppress angiogenesis in pituitary tumors.